{"id":"W2375203420","doi":"10.1200/jco.2006.24.18_suppl.5084","title":"Phase II study of sorafenib (BAY 43–9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Sorafenib; Clinical endpoint; Internal medicine; Phases of clinical research; Refractory (planetary science); Ovarian cancer; Oncology; Gastroenterology; Cancer; Clinical trial; Surgery; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002817886,0.001877459,0.00221107,0.0005090041,0.0004526234,0.00102559,0.001092916,0.001580562,0.005510674],"category_scores_gemma":[0.001274754,0.0006505303,0.001166392,0.0005045208,0.0009178433,0.000850425,0.0005570613,0.003099324,0.001228706],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001118142,"about_ca_system_score_gemma":0.002402131,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001052797,"about_ca_topic_score_gemma":0.002011692,"domain_scores_codex":[0.9993225,0.000401018,0.00002399275,0.00009489569,0.00005721963,0.0001004821],"domain_scores_gemma":[0.9990727,0.0001200736,0.0001755307,0.00007598455,0.00005350517,0.0005021862],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.746065,0.07745644,0.007388505,0.001346854,0.001527853,0.0005106603,0.0003744205,0.003543909,0.02820337,0.000380556,0.0107666,0.1224359],"study_design_scores_gemma":[0.796802,0.1908132,0.007549251,0.00002759383,0.0002223447,0.0002454807,0.0000320822,0.001059964,0.001192109,0.0001371534,0.001898278,0.00002054875],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9893931,0.001952792,0.0004993225,0.0009674931,0.0001347811,0.003962323,0.0012371,0.0001555938,0.001697493],"genre_scores_gemma":[0.9769628,0.002344301,0.00263346,0.001777765,0.0003596402,0.007015995,0.004508351,0.00006749504,0.004330039],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005510674,"threshold_uncertainty_score":0.01843506,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09325489722830269,"score_gpt":0.4701086753564609,"score_spread":0.3768537781281582,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}